Learning Objectives:

1. Understand the reasons for failure of TME-directed immunotherapeutics.

2. Review guiding principles for cancer immunotherapeutics development.

3. Understand potential approaches for increasing tumor-reactive T cells in patients, and reversing T Cell ignorance

Session date: 
01/10/2022 - 12:00pm to 1:00pm CST
KCBD RM:1103
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Scott Antonia, MD, PhD